Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study

• Main Authors: Renfeng Fan (Author), Xiaoyuan Huang (Author), Xuanxuan Nian (Author), Zhiqiang Ou (Author), Jian Zhou (Author), Jiayou Zhang (Author), Peiyu Zeng (Author), Wei Zhao (Author), Jinglong Deng (Author), Wei Chen (Author), Shaomin Chen (Author), Kai Duan (Author), Yingshi Chen (Author), Xinguo Li (Author), Jikai Zhang (Author), Xiaoming Yang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

To control seasonal influenza epidemics in elders, a quadrivalent, inactivated, split-virion influenza vaccine (IIV4) comprising A and B lineages is produced for young individuals and adults aged ≥60 years. In this phase III, randomized, double-blind, active-controlled trial, we compared safety and...